Stock VRTX VERTEX PHARMACEUTICALS INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

Company Vertex Pharmaceuticals Incorporated

Equities

VRTX

US92532F1003

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-23 pm EDT 		5-day change 1st Jan Change
450.8 USD +0.73% Intraday chart for Vertex Pharmaceuticals Incorporated +2.31% +10.79%
May. 22 Vertex Pharmaceuticals Insider Sold Shares Worth $6,795,294, According to a Recent SEC Filing MT
May. 21 ADDvise Group’s Axelerist Bags $1.4 Million Order for Medical, Lab Equipment MT

Business Summary

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.

Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Number of employees: 5,400

Sales per Business

USD in Million2022Weight2023Weight Delta
Pharmaceutical
100.0 %
8,931 100.0 % 9,869 100.0 % +10.51%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
61.2 %
5,699 63.8 % 6,040 61.2 % +5.98%
Europe
31.5 %
2,706 30.3 % 3,109 31.5 % +14.91%
Other
7.3 %
526 5.9 % 720 7.3 % +36.87%

Managers

Managers TitleAgeSince
Reshma Kewalramani CEO
 Chief Executive Officer 51 17-01-31
Jeffrey Leiden CHM
 Chairman 68 09-07-07
Charles Wagner DFI
 Director of Finance/CFO 55 19-04-09
Mike Tirozzi CTO
 Chief Tech/Sci/R&D Officer - 18-12-31
Carmen Bozic CTO
 Chief Tech/Sci/R&D Officer 61 19-04-30
Stuart Arbuckle COO
 Chief Operating Officer 58 12-09-03
Mark Bunnage CTO
 Chief Tech/Sci/R&D Officer - 15-12-31
Edward Atkinson CTO
 Chief Tech/Sci/R&D Officer 58 20-06-30
David Altshuler CTO
 Chief Tech/Sci/R&D Officer 59 14-12-31
Susie Lisa IRC
 Investor Relations Contact - 22-08-31

Members of the board

Members of the board TitleAgeSince
Alan Garber BRD
 Director/Board Member 68 17-06-07
Jeffrey Leiden CHM
 Chairman 68 09-07-07
Bruce Sachs BRD
 Director/Board Member 64 97-12-31
Lloyd Carney BRD
 Director/Board Member 62 19-02-20
Michel Lagarde BRD
 Director/Board Member 50 23-10-04
Sangeeta Bhatia BRD
 Director/Board Member 55 15-06-17
Diana McKenzie BRD
 Director/Board Member 59 20-06-02
Suketu Upadhyay BRD
 Director/Board Member 55 22-05-17
Nancy Thornberry BRD
 Director/Board Member 67 Dec. 04
Reshma Kewalramani CEO
 Chief Executive Officer 51 17-01-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 258,053,387 257,750,557 ( 99.88 %) 0 99.88 %

Shareholders

NameEquities%Valuation
Capital Research & Management Co. (World Investors)
10.03 %
25,902,938 10.03 % 10 302 M $
Capital Research & Management Co. (World Investors)
9.898 %
25,567,184 9.898 % 10 168 M $
Vanguard Fiduciary Trust Co.
8.779 %
22,676,518 8.779 % 9 018 M $
BlackRock Advisors LLC
6.648 %
17,173,572 6.648 % 6 830 M $
STATE STREET CORPORATION
4.648 %
12,006,483 4.648 % 4 775 M $
Fidelity Management & Research Co. LLC
4.132 %
10,673,520 4.132 % 4 245 M $
AllianceBernstein LP
2.837 %
7,327,172 2.837 % 2 914 M $
JPMorgan Investment Management, Inc.
2.318 %
5,986,553 2.318 % 2 381 M $
Geode Capital Management LLC
2.250 %
5,813,036 2.250 % 2 312 M $
Capital Research & Management Co. (Global Investors)
2.224 %
5,743,882 2.224 % 2 284 M $
NameEquities%Valuation
Bram Bradesco Asset Management S/A DTVM
0.000224 %
2,314 0.000224 % 227 690 $
XP Allocation Asset Management Ltda.
0.000070 %
722 0.000070 % 71 042 $
Santander Brasil Gestão de Recursos Ltda.
0.000017 %
177 0.000017 % 17 416 $

Company contact information

Vertex Pharmaceuticals, Inc.

50 Northern Avenue

02210, Boston

+617 341 6100

http://www.vrtx.com
address Vertex Pharmaceuticals Incorporated(VRTX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
447.5 USD
Average target price
462.8 USD
Spread / Average Target
+3.41%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+10.79% 115B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.65% 106B
BIONTECH SE Stock BioNTech SE
-6.20% 24.69B
ARGENX SE Stock argenx SE
-2.33% 21.97B
GENMAB A/S Stock Genmab A/S
-6.03% 19.27B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.41% 17.56B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-40.50% 17.32B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.64% 14.03B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+31.84% 12.13B
LEGEND BIOTECH CORPORATION Stock Legend Biotech Corporation
-34.35% 7.77B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. VRTX Stock
  4. Company Vertex Pharmaceuticals Incorporated